Home › Pancreatic Cancer › NCT07737171

Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions: A Pancardinal-4 Prospective Registry

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy
* Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically

Exclusion Criteria:

* Patients with co-existing malignancies of other organs (or a prior history of such)
* Patients unable to provide informed consent
* Patients unable to complete follow-up

About the study

This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.

What is being tested

• Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) (device)

Sponsor: The University of Texas Health Science Center, Houston · Participants: 60 · Started: Apr 7, 2026

Contact the study team

• Amatullah Alibhai, MBA · Phone: 713-500-6658
• Nicole Fatheree, BBA · Phone: 713-500-5669

Official record on ClinicalTrials.gov — NCT07737171

Locations in the U.S.

Conditions

• Pancreatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.